Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment. The trial did not meet key end-points ... Oct 21
Glenmark the first company to launch Favipiravir in India now launches 400 mg tablets... Aug 06
Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India... Jul 13
CSIR and Laxai Sciences to seek regulatory approval for clinical trials on COVID-19 patients using combinations of antiviral and host-directed therapies... Jul 08
Glenmark is the first pharmaceutical company in India to receive approval for antiviral Favipiravir for mild to moderate covid patients... Jun 20
Phase 3 Trials will be carried out at King George’s Medical University, Dr Ram Manohar Lohia Institute and Lucknow Medical College... Jun 19
Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India... May 26
Glenmark to commence phase 3 clinical trial to test combined efficacy Favipiravir and Umifenovir ... May 26
-Advertisements-